Syneuria
Syneuria is developing a precision neuropharmacology platform designed to personalize treatment for neurological conditions by integrating patient-specific biological and clinical data. The company focuses on identifying biomarkers that predict therapeutic response, aiming to help clinicians move beyond trial-and-error prescribing toward more targeted drug selection and dosing.
- Healthcare Technology
- Digital Health
- Biotechnology
- Data & Analytics
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
The field of neuropharmacology often relies on generalized treatment protocols that do not account for individual variability in patient biology, genetics, and drug response. This one-size-fits-all approach can lead to suboptimal therapeutic outcomes, adverse drug reactions, and prolonged trial-and-error periods for patients with neurological conditions.
Solution
Syneuria is building a precision neuropharmacology platform that aims to personalize neuro-medicine by integrating patient-specific data to guide drug selection and dosing. The company's approach focuses on identifying biomarkers and patient characteristics that predict treatment response, enabling clinicians to move beyond trial-and-error prescribing. While detailed product capabilities are not yet publicly disclosed, the stated mission centers on delivering personalized neuro-medicine through data-driven pharmacological insights.
Target Audience
Primary customers are expected to be neurologists, psychiatrists, and clinical researchers seeking more precise pharmacological tools for treating neurological and psychiatric disorders, as well as healthcare institutions focused on personalized medicine programs.
Features
- Precision neuropharmacology platform designed to tailor treatments to individual patient profiles
- Focus on integrating biological and clinical data to inform drug selection decisions
- Emphasis on biomarker identification for predicting therapeutic response in neurological care